Management of RA medications in pregnant patients

Nature Reviews Rheumatology

Volumn 5, Issue 7, 2009, Pages 382-390

  østensen, Monika ^a   Förger, Frauke ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOSPORIN; GLUCOCORTICOID; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ANIMAL; DRUG CONTRAINDICATION; FEMALE; GESTATIONAL AGE; HUMAN; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RHEUMATOID ARTHRITIS;

ACETAMINOPHEN; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; CYCLOSPORINE; FEMALE; GESTATIONAL AGE; GLUCOCORTICOIDS; HUMANS; IMMUNOCONJUGATES; ISOXAZOLES; METHOTREXATE; PREGNANCY; PREGNANCY COMPLICATIONS; SULFASALAZINE; YOUNG ADULT;

EID: 70349577501     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.103     Document Type: Review

References (79)

1. Doran, M. F., Pond, G. R., Growson, W., O’Fallon, M. & Gabriel, S. E. Trends in incidence and mortality in rheumatoid arthritis in rochester, Minnesota, over a forty year period. Arthritis Rheum. 46, 625–631 (2002).
2. Barrett, J. H., Brennan, P., Fiddler, M. & Silman, A. J. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 42, 1219–1227 (1999).
3. de Man, Y. A., Dolhain, R. J., van de Geijn, F. E., willemsen, S. P. & Hazes, J. M. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 59, 1241–1248 (2008).
4. Ostensen, M. et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 8, 209 (2006).
5. Ostensen, M., Hartmann, H. & salvesen, K. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J. Rheumatol. 27, 1872–1875 (2000).
6. Feldkamp, M. & Carey, J. C. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in early weeks of pregnancy. Teratology 47, 533–539 (1993).
7. Bawle, E. V., Conard, J. V. & weiss, L. Adult and two children with fetal methotrexate syndrome. Teratology 57, 51–55 (1998).
8. Kozlowski, R. D. et al. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am. J. Med. 88, 589–592 (1990).
9. Lewden, B. et al. Low dose weekly methotrexate in the first trimester of pregnancy: results of a French collaborative study. J. Rheumatol. 31, 2360–2365 (2004).
10. Visser, K. et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3e initiative. Ann. Rheum. Dis. doi:10.1136/ard.2008.094474.
11. Chakravarty, E. F., Sanchez-Yamamoto, D. & Bush, T. M. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcome. J. Rheumatol. 30, 241–246 (2003).
12. Buckley, L. M., Bullaboy, C. A., Leichtman, L. & Marquez, M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum. 40, 971–973 (1997).
13. Brent, R. L. Teratogen update: reproductive risks of leflunomide (AravaTM), a pyrimidine synthesis inhibitor: counselling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63, 106–112 (2001).
14. Chambers, C. D., Tutuncu, Z. N., Johnon, D. & Jones, K. L. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res. Ther. 8, 215–225 (2006).
15. De santis, M., straface, G., Cavaliere, A., Carducci, B. & Caruso, A. Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome. Ann. Rheum. Dis. 64, 1096–1097 (2005).
16. Neville, C. E. & McNally, J. Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology (Oxford) 46, 1506 (2007).
17. Chambers, C. D., Johnson, D. L., Macaraeg, G. R. & Jones, K. L. Pregnancy outcome following early gestational exposure to leflunomide: the OTis rheumatoid arthritis in pregnancy study [abstract 251]. Pharmacoepidemiol. Drug Safety 13 (Suppl.), s126 (2004).
18. Kremer, J. M. et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144, 865–876 (2006).
19. Klink, D. T., van Elburg, R. M., Schreurs, M. W. & van Well, G. T. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin. Dev. Immunol. 2008, 271363 (2008).
20. Herold, M., Schnohr, S. & Bittrich, H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J. Clin. Oncol. 19, 3439 (2001).
21. Decker, M., Rothermundt, C., Hollander, G., Tichelli, A. & Rochlitz, C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 7, 693–694 (2006).
22. Friedrichs, B. et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91, 1426–1427 (2006).
23. Kimby, E., sverrisdottir, A. & Elinder, G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Europ. J. Haematol. 72, 292–295 (2004).
24. Scully, M. et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul. Fibrinolysis 17, 459–463 (2006).
25. Ojeda-Uribe, M., Gilliot, C., Jung, G., Drenou, B. & Brunot, A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J. Perinatol. 26, 252–255 (2006).
26. Katz, J. A. et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am. J. Gastroenterol. 99, 2385–2392 (2004).
27. Roux, C. H., Brocq, O., Breuil, V., Albert, C. & Euller-Ziegler, L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology (Oxford) 46, 695–698 (2006).
28. Hyrich, K., Symmons, D., Watson, K. & Silman, A. Pregnancy outcome in women who were exposed to anti-TNF agents: results from a national population register. Arthritis Rheum. 54, 2701–2702 (2006).
29. Chambers, C. D., Johnson, D. L. & Jones, K. L. Pregnancy outcome in women exposed to adalimumab: the OTis Autoimmune Diseases in Pregnancy Project [abstract 514]. Arthritis Rheum. 54 (Suppl.), s251 (2006).
30. Berthelot, J. M. et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76, 28–34 (2009).
31. Vasiliauskas, E. A. et al. Evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin. Gastroenterol. Hepatol. 4, 1255–1258 (2006).
32. Mahadevan, U. et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 132 (Suppl. 1), A-144.
33. Mahadevan, U. et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn’s disease. Aliment. Pharmacol. Ther. 21, 733–738 (2005).
34. Carter, J. D., Valeriano, J. & Vasey, F. B. Tumor necrosis factor-alpha inhibition and vATer association: a causal relationship? J. Rheumatol. 33, 1014–1017 (2006).
35. Carter, J. D., Ladhani, A., Ricca, L. R., Valeriano, J. & Vasey, F. B. A safety assessment of TNF Antagonists during pregnancy: a review of the Food and Drug Administration database. J. Rheumatol. 36, 635–641 (2009).
36. Ostensen, M. Are TNF inhibitors safe in pregnancy? Nat. Rev. Rheumatol. 5, 184–185 (2009).
37. Patlas, N. et al. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60, 68–73 (1999).
38. Rutgers-Verhage, A. R., Devries, T. W. & Torringa, M. J. No effects of bisphosphonates on the human fetus. Birth Defects Res. A Clin. Mol. Teratol. 67, 203–204 (2003).
39. Ornoy, A., Wajnberg, R. & Diav-Citrin, O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod. Toxicol. 22, 578–579 (2006).
40. Levy, S. et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44, 428–430 (2008).
41. Costedoat-Chalumeau, N. et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 46, 1123–1124 (2002).
42. Hart, C. N. & Naunton, R. F. The ototoxicity of chloroquine phosphate. Arch. Otolaryngol. 80, 407–412 (1964).
43. Buchanan, N. M. M. et al. Hydoxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann. Rheum. Dis. 55, 486–488 (1996).
44. Costedoat-Chalumeau, N. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 48, 3207–3211 (2003).
45. Clowse, M. E. B., Magder, L., witter, F. & Petri, M. Hydoxychloroquine in lupus pregnancy. Arthritis Rheum. 54, 3640–3647 (2006).
46. Klinger, G. et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358, 813–814 (2001).
47. Mogadam, M., Dobbins, W. O., Korelitz, B. I. & Ahmed, S. W. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80, 72–76 (1981).
48. Norgard, B., Czeizel, A. E., rockenbauer, M., Olsen, J. & sorensen, H. T. Population-based case control study of the safety of sulphasalazine used during pregnancy. Aliment. Pharmacol. Ther. 15, 483–486 (2001).
49. Moskovitz, D. N. et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am. J. Gastroenterol. 99, 656–661 (2004).
50. Rahimi, R., Nikfar, S., Rezaie, A. & Abdollahi, M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod. Toxicol. 25, 271–275 (2008).
51. Hernandez-Diaz, S., Werler, M. M., Walker, A. M. & Mitchell, A. A. Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med. 343, 1608–1614 (2000).
52. Katchamart, W., Trudeau, J., Phumethum, V. & Bombardier, C. The efficacy and toxicity of Methotrexate (MTX) monotherapy vs. MTX combination therapy with non-biologic diseasemodifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. Ann. Rheum. Dis. doi:10.1136/ard.2008.099861
53. Friedman, J. M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 65, 240–261 (2002).
54. Goldstein, L. H. et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res. A Clin. Mol. Teratol. 79, 696–701 (2007).
55. Norgard, B., Pedersen, L., Christensen, L. A. & Sorensen, H. T. Therapeutic drug use in women with Crohn’s disease and birth outcomes: A Danish nationwide cohort study. Am. J. Gastroenterol. 102, 1406–1413 (2007).
56. Davison, J. M., Dellagrammatikas, H. & Parkin, J. M. Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br. J. Obstet. Gynaecol. 92, 233–239 (1985).
57. Armenti, V. T. et al. Report from the National Transplantation Pregnancy registry (NTPr): outcomes of pregnancy after transplantation. in: Clinical Transplants 2004 (eds Cecka, J. M. & Terasaki, P. I.) 103–114 (UCLA, Los Angeles, 2004).
58. Lamarque, V., Leleu, M. F., Monka, C. & Krupp, P. Analysis of 629 pregnancy outcomes in transplant recipients treated with sandimmun. Transplant. Proc. 29, 2480 (1997).
59. Bar Oz, B., Hackman, R., Einarson, T. & Koren, G. Pregnancy outcome after CsA therapy during pregnancy: a meta-analysis. Transplantation 71, 1051–1055 (2001).
60. Shaheen, F. A. M., Ai-sulaiman, M. H. & Ai-Khader, A. A. Long-term nephrotoxicity after exposure to CsA in utero. Transplantation 56, 224–225 (1993).
61. Reinisch, J. M. & Simon, N. G. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 202, 436–438 (1978).
62. Ostensen, M., Fuhrer, L., Mathieu, R., Seitz, M. & Villiger, P. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann. Rheum. Dis. 63, 1212–1217 (2004).
63. Cowchock, F. S., Reece, E. A., Balaban, D., Branch, D. W. & Plouffe, L. Repeated fetal losses associated with antiphospholipid antibodies; a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. J. Obstet. Gynecol. 166, 1318–1323 (1992).
64. Carmichael, S. L. et al. Maternal corticosteroid use and orofacial clefts. Am. J. Obstet. Gynecol. 197, 585e1–585e7 (2007).
65. Park-wyllie, L. et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 62, 385–392 (2000).
66. Mendonca, L. L. F., Khamashta, M. A., Nelson-Piercy, C., Hunt, B. J. & Hughes, G. R. V. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford) 39, 880–882 (2000).
67. Uhler, M. L., Hsu, J. W., Fisher, S. G. & Zinaman, M. J. The effect of nonsteroidal ntiinflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil. Steril. 76, 957–961 (2001).
68. Ofori, B., Oraichi, D., Blais, L., Rey, E. & Berard, A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case–control study. Birth Defects Res. B. Dev. Reprod. Toxicol. 77, 268–279 (2006).
69. Cleves, M. A. et al. Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NsAiDs), and muscular ventricular septal defects. National Birth Defects Prevention study. Birth Defects Res. A Clin. Mol. Teratol. 70, 107–113 (2004).
70. Kozer, E. et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am. J. Obstet. Gynecol. 187, 1623–1630 (2002).
71. Heinonen, O. P., Slone, D. & Shapiro, S. Birth defects and drugs in pregnancy 286–295 (Publishing sciences Group, Littleton, MA, 1977).
72. Nielsen, G. L., sorensen, H. T., Larsen, H. & Pedersen, L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case–control study. Br. Med. J. 322, 266–270 (2001).
73. Momma, K. & Takeuchi, H. Constriction of the ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins 26, 631–643 (1983).
74. Paladini, D., Marasini, M. & Volpe, P. Severe ductal constriction in the third-trimester fetus following maternal self-medication with nimesulide. Ultrasound Obstet. Gynecol. 25, 357–361 (2005).
75. Stika, C. S. et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am. J. Obstet. Gynecol. 187, 653–660 (2002).
76. Alano, M. A., Ngougmna, E., Ostrea, E. M. Jr. & Konduri, G. G. Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 107, 519–513 (2001).
77. Hickok, D. E., Hollenbach, K. A., Reilley, S. F. & Nyberg, D. A. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am. J. Obstet. Gynecol. 160, 1525–1531 (1989).
78. Kaplan, B. S, Restaino, I., Raval, D. S., Gottlieb, R. P. & Bernstein, J. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr. Nephrol. 8, 700–704 (1994).
79. Ostensen, M., von Esebeck, M. & Villiger, P. M. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J. Rheumatol. 34, 1266–1269 (2007).